April 14, 2019
Vital Therapies, Precipio, Chimerix, ContraFect and PhaseBio Pharmaceuticals were last week's top gainers.
December 2, 2018
Arsanis, Tyme Technologies, CohBar, Cocrystal Pharma and Contrafect were last week's top gainers.
July 27, 2018
ContraFect (NASDAQ:CFRX) has announced the pricing of its underwritten public offering of five million shares of its common stock at...
March 15, 2018
ContraFect (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant...
July 20, 2017
ContraFect priced its upcoming public offering of common stock and warrants at $40 million.
May 25, 2017
ContraFect began a Phase 2 study to evaluate CF-301 as a treatment of Staphylococcus aureus bacteremia.
March 13, 2017
ContraFect (NASDAQ: CFRX) announced that CEO Dr. Steven C. Gilman will take a medical leave starting on March 16.